Physician profile
Seth Eiland
NPI 1588144604
$5,034.74
in general payments reported to CMS, 2019-2025
20 companies · $1,368 in 2025
The $1,368 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $387 · 2022: $279 · 2023: $805 · 2024: $2,197 · 2025: $1,368.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,149 · Consulting Fee: $115 · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,149.18 |
| Consulting Fee | $115.00 |
| Education | $105.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,083.65 | 2021-2025 | |
| Neuronetics, INC. | $553.25 | 2023-2024 | Neurostar Tms Therapy System |
| Otsuka America Pharmaceutical, INC. | $532.21 | 2021-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $531.85 | 2021-2025 | Caplyta |
| Axsome Therapeutics, INC. | $485.05 | 2023-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $321.36 | 2022-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Takeda Pharmaceuticals U.S.A., INC. | $293.11 | 2021-2025 | Trintellix |
| Lundbeck LLC | $273.04 | 2023-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $186.75 | 2022-2025 | Qelbree |
| Neurocrine Biosciences, INC. | $163.58 | 2024-2025 | Ingrezza |
| Corium, LLC | $121.45 | 2024-2025 | Azstarys |
| Janssen Scientific Affairs, LLC | $115.00 | 2025 | Spravato |
| Janssen Pharmaceuticals, INC | $107.72 | 2023-2024 | Spravato |
| Tris Pharma INC | $52.62 | 2025 | Dyanavel Xr |
| Neos Therapeutics, Lp | $52.20 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $46.97 | 2024-2025 | Aplenzin |
| E.R. Squibb & Sons, L.L.C. | $45.71 | 2025 | Cobenfy |
| Vertical Pharmaceuticals, LLC | $36.29 | 2024 | Relexxii |
| Alkermes, INC. | $17.54 | 2025 | Aristada, Lybalvi |
| Biogen, INC. | $15.39 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seth Eiland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.